The potential for Abbott Laboratories' Lingo partnership with Alphabet (Google) to usher in a new era of AI-powered health solutions is being examined.

Analysts are providing their perspectives on several healthcare companies, including Abbott Laboratories (ABT), Lemaitre Vascular (LMAT), and Harmony Biosciences Holdings (HRMY).

An analysis compares Abbott Laboratories and Eli Lilly to determine which healthcare stock presents a better investment opportunity for 2026.

An analysis compares the differing trajectories of healthcare giants Johnson & Johnson and Abbott Laboratories, highlighting their current market positions and future outlooks.

Analysts are anticipating healthy growth for Abbott Laboratories in its Q2 earnings, with expectations largely backed by the recent acquisition of Exact Sciences. The acquisition is projected to contribute positively to the company's financial performance.

Abbott Laboratories' shares saw gains after Baird analysts issued a new 'Outperform' rating, citing a positive growth outlook for the company.

Abbott Laboratories is set to announce its second-quarter 2026 earnings. The report will provide insights into the company's financial performance and future outlook, with investors closely watching for key metrics and guidance.

Goldman Sachs has reaffirmed its 'Buy' rating for Abbott Laboratories (ABT) stock, indicating continued confidence in the healthcare company's investment potential.

Abbott Laboratories' stock concluded a six-session losing streak, indicating a potential turnaround in its recent market performance.

Abbott Laboratories (ABT) has received both FDA Clearance and the CE Mark for its next-generation Ultreon™ 3.0 Software, expanding its availability.

This article summarizes Wednesday's key research calls from Wall Street analysts concerning companies such as Abbott Laboratories, Airbnb, Biogen, and others.

Abbott Laboratories' stock has been trending lower, prompting investors and analysts to examine the factors contributing to its recent decline in the market.

Numerous companies, including The Travelers Companies, Charles Schwab, and Abbott Laboratories, have released or previewed their first-quarter 2026 earnings reports. These summaries and transcripts provide insights into their financial performance for the period.

Abbott Laboratories (ABT) has officially announced the successful completion of its acquisition of Exact Sciences, a significant corporate development.

Abbott Laboratories (ABT) has introduced XIENCE Skypoint, a new technology aimed at advancing cardiovascular treatment options in India.

Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal  Bloomberg.com

Abbott Laboratories has announced a dividend of $0.63 per share, providing an update on its shareholder returns.

This article analyzes whether Johnson & Johnson or Abbott Laboratories offers a more compelling growth story in the healthcare sector following their recent earnings reports.

Matrix Asset Advisors has made changes to its Large Cap Value Portfolio, adding Abbott Laboratories (ABT) and McDonald's (MCD) to its holdings. Concurrently, the firm has exited its position in Nestlé (NSRGY).

An analysis compares Abbott Laboratories and Johnson & Johnson to determine which healthcare stock presents a better investment opportunity for the year 2026.

Abbott Laboratories' stock saw a significant increase, with the article likely detailing the reasons behind this positive movement in its share price.

Baird has initiated coverage on Abbott Laboratories (ABT) stock, assigning it an Outperform rating.

This report highlights the best Wall Street analyst research calls for Wednesday, covering companies such as Abbott Laboratories, Dow, Lockheed Martin, Salesforce, and SpaceX.

Abbott Laboratories (ABT) is highlighted as one of the best bargain stocks available for purchase in June.

Investors are reportedly exercising caution regarding Abbott Laboratories, indicating potential concerns about the company's future performance or market position.

Abbott Laboratories' stock has fallen to a 52-week low, but company insiders are reportedly purchasing shares of the blue-chip dividend payer.

Polen Focus Growth, an investment fund, sold its holdings in both Abbott Laboratories and Boston Scientific during the first quarter. The fund cited competition concerns as a reason for divesting its stake in Boston Scientific.

This article provides a financial comparison between two medical device companies, Abbott Laboratories and Dexcom, to determine which might be a better stock investment.

Abbott Laboratories experienced a significant drop in its stock price on Thursday, with the article exploring the reasons behind the decline.

Abbott Laboratories released a summary of its first-quarter 2026 earnings call, outlining its financial performance for the period.

An article provides a preview of what to expect from Abbott Laboratories' upcoming earnings report.

An article examines if Abbott Laboratories' stock is underperforming the Nasdaq index.

Shareholders of Exact Sciences have given their approval for the company's acquisition by Abbott Laboratories.

An analysis compares AbbVie and Abbott Laboratories, examining which healthcare stock might be a better investment opportunity in 2026.

Despite Salesforce remaining down, an analyst projects over 100% returns for the company, while another analyst sees 35% gains for Abbott Laboratories, which has lost 16% this year. These forecasts suggest potential rebounds for both companies.

Abbott Laboratories (ABT) stock experienced a decline as investor concerns over its guidance and ongoing litigation overshadowed positive growth indicators.

An analysis examines whether Abbott Laboratories (ABT) stock still represents a healthcare growth opportunity despite a recent analyst target cut.

Abbott Laboratories (ABT) is reportedly facing a lawsuit concerning its PediaSure product and statements made about its impact on children's growth.

An analysis suggests that Abbott Laboratories (ABT) is considered one of the best deep value stocks for investment. The article likely details reasons for this assessment, such as financial performance or market position.

Abbott Laboratories (ABT) experienced a decline in its stock value due to challenges and headwinds faced by its nutrition business segment.

A Missouri appeals court has affirmed a $495 million ruling against Abbott Laboratories concerning a baby formula case.

Daiwa has downgraded Abbott Laboratories (ABT), indicating a belief in limited upside potential for the stock.

An article analyzes whether the recent sell-off in Abbott Laboratories stock has created a favorable entry point for investors.

Abbott Laboratories reported better-than-expected financial results, primarily driven by its medical device segment. The company also provided a 2026 forecast, projecting 6.5%-7.5% comparable sales growth, though it anticipates a $0.20 EPS dilution due to the ongoing integration of Exact Sciences.

Abbott Laboratories reported financial results that surpassed expectations, driven by strong performance in its medical device segment. However, the company also lowered its earnings outlook, citing the impact of its acquisition of Exact Sciences.

An analysis explores whether Abbott Laboratories (ABT) presents a favorable stock investment opportunity for current buyers.

Abbott Laboratories (ABT) is anticipated to see positive performance driven by a recovery in its nutrition segment.

Abbott Laboratories has reported positive clinical trial results for its Amulet 360 Left Atrial Appendage (LAA) Occluder, a device designed to prevent strokes.